Zobrazeno 1 - 10
of 86
pro vyhledávání: '"59"'
Autor:
Kåre I. Birkeland, T. E. Christensen, Anthony P. Roberts, Thue Johansen, Robert E. Ratner, U. Wendisch, Johan Jendle, Luigi F. Meneghini, Philip Home
Publikováno v:
Diabetic Medicine
Aims The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial. Health st
Autor:
Josy Reiffers, Philippe Bernard, Francis Lacombe, D. Dachary, Antoine Broustet, Michel R. Boisseau
Publikováno v:
Scandinavian Journal of Haematology. 32:429-440
In 71 adult acute myelogenous leukaemia (AML) cases, the relationship between well-known prognostic features and complete remission (CR) rate and survival was studied. These features were: (i) bone marrow karyotype classified NN, AN, AA according to
Autor:
Hiroshi Nokihara, Kazuhiko Yamada, Tomohide Tamura, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Noboru Yamamoto
Publikováno v:
Cancer Science. 98:1408-1412
To determine whether bodyweight (BW) loss, daily urine volume (UV) or furosemide use are associated with cisplatin nephrotoxicity, performance status, serum chemistries before treatment, average daily UV, maximum BW loss and use of furosemide on days
Publikováno v:
Pharmacoepidemiology and Drug Safety. 16:309-315
To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Ostergötland, Sweden.All patients with a diagnosed cerebral haemorrha
Autor:
Jukka Ollgren, Emilia Attman, Outi Lyytikäinen, Reetta Huttunen, Risto Vuento, Jaana Syrjänen, Marjatta Sinisalo, Erja Mattila
Publikováno v:
European Journal of Haematology. 107:311-317
OBJECTIVES The aim was to identify the clinical characteristics, outcome, and antimicrobial susceptibility of healthcare-associated bloodstream infections (BSIs) in hematological patients. METHODS This retrospectively collected laboratory-based surve
Autor:
Victor Biton, Enrique Carrazana, Adrian L. Rabinowicz, Eric Segal, R. Edward Hogan, David F. Cook, Daniel Tarquinio, Blanca Vazquez, Ian Miller, Kore Liow, Michael R. Sperling, Gregory D. Cascino, James W. Wheless, Dennis J. Dlugos, Jay Desai
Publikováno v:
Epilepsia
Objective Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration.
Autor:
Matthew Butler, Danielle McGeeney, Antonia Periclou, Li Yao, Brian McNamee, Lisa Borbridge, Ramesh Boinpally
Publikováno v:
Clinical Pharmacology in Drug Development
Atogepant is a selective, oral calcitonin gene–related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double‐blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single
Autor:
Haipeng Shao, Ling Zhang, Ning Dong, Lubomir Sokol, Qianxing Mo, Franco Castillo Tokumori, Todd C. Knepper, Yumeng Zhang, Ankita Tandon, Leidy Isenalumhe
Publikováno v:
American Journal of Hematology. 96:772-780
Large granular lymphocytic leukemia (LGLL) is a rare hematological malignancy that arises from cytotoxic T lymphocytes (T-LGLL) in 85% of cases and natural killer (NK) cells in the rest. A significant knowledge gap exists regarding the pathogenesis,
Autor:
Pian Zhang, Dehui Zou, Yuqin Song, Hui Liu, Wenyu Li, Su Yang, Daobin Zhou, Zhitao Ying, Jun Zhu, Jianqiu Wu, Zhao Wang, Haiyan Yang, Mingzhi Zhang, Hongxia Zheng, Ye Guo, Zisong Zhou
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 999-1011 (2021)
Cancer Medicine
Cancer Medicine
Background Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T manufacture
Autor:
Henrik E. Poulsen, Thomas F. Dejgaard, Nicklas J. Johansen, Emil List Larsen, Holger Jon Møller, Filip K. Knop, Tina Vilsbøll, Asger Lund, Henrik U. Andersen, Camilla Schlüntz, Jens P. Goetze
Publikováno v:
Johansen, N J, Dejgaard, T F, Lund, A, Schlüntz, C, Larsen, E L, Poulsen, H E, Goetze, J P, Møller, H J, Vilsbøll, T, Andersen, H U & Knop, F K 2020, ' Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes : A randomized double-blind placebo-controlled trial ', Diabetes, Obesity and Metabolism, vol. 22, no. 9, pp. 1639-1647 . https://doi.org/10.1111/dom.14078
Aims: To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials and methods: In a randomized, double-blind, p